CBUS earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.01. Updated 2026-07-23.
Cibus (CBUS) Research Hub
Cibus (CBUS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.57 USD (-1.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.01, market cap 0.08B. This hub links to the full technical, earnings and options research available for CBUS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.57 USD (-1.26%) |
| 52-week range | 1.25 USD – 2.43 USD |
| Trend regime | Range |
| 14-day RSI | 29.3 (Oversold) |
| Trailing P/E | -1.01 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CBUS
Covered Call on CBUS: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CBUS: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CBUS: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
CBUS technical analysis: range, last 1.57 USD, RSI 29.3, 52w range 1.25 USD–2.43 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CBUS in?
Cibus (CBUS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CBUS in an uptrend or downtrend?
As of 2026-09-11, CBUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CBUS's trailing P/E ratio?
CBUS's trailing P/E is -1.01, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does CBUS next report earnings?
CBUS is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.31 USD.